Appendix 6 - 60 day FRN

Federal Register / Vol. 73, No. 7 / Thursday, January 10, 2008 / Notices
EQR DATA DICTIONARY—APPENDIX F.
RATE UNITS
Rate units

Definition

$/KV ..................
$/KVA ...............
$/KVR ...............
$/KW .................
$/KWH ..............
$/KW–DAY .......
$/KW–MO .........
$/KW–WK .........
$/KW–YR ..........
$/MW ................
$/MWH ..............
$/MW–DAY .......
$/MW–MO ........
$/MW–WK ........
$/MW–YR .........
$/MVAR–YR .....
$/RKVA .............
CENTS .............
CENTS/KVR .....
CENTS/KWH ....
FLAT RATE ......

dollars per kilovolt.
dollars per kilovolt amperes.
dollars per kilovar.
dollars per kilowatt.
dollars per kilowatt hour.
dollars per kilowatt day.
dollars per kilowatt month.
dollars per kilowatt week.
dollars per kilowatt year.
dollars per megawatt.
dollars per megawatt hour.
dollars per megawatt day.
dollars per megawatt
month.
dollars per megawatt
week.
dollars per megawatt year.
dollars per megavar year.
dollars per reactive kilovar
amperes.
cents.
cents per kilovolt amperes.
cents per kilowatt hour.
rate not specified in any
other units.

[FR Doc. E8–184 Filed 1–9–08; 8:45 am]
BILLING CODE 6717–01–P

FEDERAL HOUSING FINANCE BOARD
Sunshine Act Meeting Notice;
Announcing a Partially Open Meeting
of the Board of Directors
The open meeting of the
Board of Directors is scheduled to begin
at 10 am on Tuesday, January 15, 2008.
The closed portion of the meeting will
follow immediately the open portion of
the meeting.
PLACE: Board Room, First Floor, Federal
Housing Finance Board, 1625 Eye
Street, NW., Washington, DC 20006.
STATUS: The first portion of the meeting
will be open to the public. The final
portion of the meeting will be closed to
the public.
TIME AND DATE:

MATTER TO BE CONSIDERED AT THE OPEN
PORTION: Federal Home Loan Bank of

San Francisco—Waiver of Certain AHP
Regulations to Permit Refinancing/
Modification of Subprime Mortgage
Loans.

yshivers on PROD1PC62 with NOTICES

MATTER TO BE CONSIDERED AT THE CLOSED
PORTION: Periodic Update of

Examination Program Development and
Supervisory Findings.
CONTACT PERSON FOR MORE INFORMATION:
Shelia Willis, Paralegal Specialist,
Office of General Counsel, at 202–408–
2876 or [email protected].
Dated: January 8, 2008.

VerDate Aug<31>2005

14:29 Jan 09, 2008

Jkt 214001

By the Federal Housing Finance Board.
Neil R. Crowley,
Acting General Counsel.
[FR Doc. 08–85 Filed 1–8–08; 3:59 pm]
BILLING CODE 6725–01–P

FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR Part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The application also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
Web site at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than February 5,
2008.
A. Federal Reserve Bank of Kansas
City (Todd Offerbacker, Assistant Vice
President) 925 Grand Avenue, Kansas
City, Missouri 64198–0001:
1. Young Partners, L.P., and its
general partner, Young Corporation,
and Citizens Bancshares Company, all
of Chillicothe, Missouri, and First
Community Bancshares, Inc., and FCB
Acquisition Corp., both of Overland
Park, Kansas; to acquire NKC
Bancshares, Inc., and thereby indirectly
acquire Norbank, both of North Kansas
City, Missouri. In connection with this
application, FCB Acquisition Corp, has

PO 00000

Frm 00028

Fmt 4703

Sfmt 4703

1889

applied to become a bank holding
company by merging with NKC
Bancshares Inc.
Board of Governors of the Federal Reserve
System, January 7, 2008.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E8–262 Filed 1–9–08; 8:45 am]
BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–08–0008]

Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Maryam I. Daneshvar,
CDC Acting Reports Clearance Officer,
1600 Clifton Road, MS–D74, Atlanta,
GA 30333 or send an e-mail to
[email protected].
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Hazardous Substances Emergency
Events Surveillance (HSEES)—
Extension—(0923–0008), Agency for
Toxic Substances and Disease Registry
(ATSDR), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
The Agency for Toxic Substances and
Disease Registry (ATSDR) is mandated

E:\FR\FM\10JAN1.SGM

10JAN1

1890

Federal Register / Vol. 73, No. 7 / Thursday, January 10, 2008 / Notices

pursuant to the 1980 Comprehensive
Environmental Response Compensation
and Liability Act (CERCLA) and its 1986
Amendments, The Superfund
Amendments and Reauthorization Act
(SARA), to prevent or mitigate adverse
human health effects and diminished
quality of life resulting from the
exposure to hazardous substances into
the environment. The primary purpose
of this activity, which ATSDR has
supported since 1992, is to develop,
implement, and maintain a state-based
surveillance system for hazardous
substances emergency events which can
be used to (1) describe the distribution
of the hazardous substances releases; (2)
describe the public health consequences
(morbidity, mortality, and evacuations)
associated with the events; (3) develop
strategies to reduce future public health
consequences. The study population
will consist of all hazardous substance
non permitted acute releases within the
14 states (Colorado, Florida, Iowa,

personnel; or researched by the HSEES
coordinator using material safety data
sheets, and chemical handbooks. There
is a reduction in the annual burden
hours per response because of the
reduction in number of states from 15 to
14 and because of a change in the case
definition of an HSEES event in 2005,
which excludes stack emissions of
oxides of nitrogen (NOX), oxides of
sulfur (SOx), and carbon monoxide (CO)
when they are not mixed with another
hazardous substance.
The HSEES public use data set is
available on the ATSDR HSEES Web
site. Interested parties complete a brief
description of who will be using the
data and for what purpose in order to
download the data. This allows ATSDR
to widely distribute the data and track
its usefulness.
There is no cost to the respondents
other than their time.

Louisiana, Michigan, Minnesota, New
Jersey, New York, North Carolina,
Oregon, Texas, Utah, Washington, and
Wisconsin) participating in the
surveillance system.
Until this system was developed and
implemented, there was no national
public health-based surveillance system
to coordinate the collation, analysis, and
distribution of hazardous substances
emergency release data to public health
practitioners. It was necessary to
establish this national surveillance
system which describes the public
health impact of hazardous substances
emergencies on the health of the
population of the United States. The
data collection form will be completed
by the state health department
Hazardous Substances Emergency
Events Surveillance (HSEES)
coordinator using a variety of sources
including written and oral reports from
environmental protection agencies,
police, firefighters, emergency response

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Respondents

Participating State Health Department HSEES Coordinators .........................
Persons interested in HSEES data through Web site .....................................
Total ..........................................................................................................

Dated: January 4, 2008.
Marilyn S. Radke,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. E8–270 Filed 1–9–08; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007D–0493]

International Conference on
Harmonisation; Draft Guidance on
Q8(R1) Pharmaceutical Development;
Availability
AGENCY:

Food and Drug Administration,

HHS.

yshivers on PROD1PC62 with NOTICES

ACTION:

Notice.

SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance entitled
‘‘Q8(R1) Pharmaceutical Development
Revision 1.’’ The draft guidance was
prepared under the auspices of the
International Conference on
Harmonisation of Technical
Requirements for Registration of

VerDate Aug<31>2005

14:29 Jan 09, 2008

Jkt 214001

14
500
514

Pharmaceuticals for Human Use (ICH).
The draft guidance is an annex to the
parent ICH guidance entitled ‘‘Q8
Pharmaceutical Development’’ (71 FR
29344, May 22, 2006) (ICH Q8). It
provides further clarification of key
concepts outlined in ICH Q8 and
describes the principles of quality by
design (QbD). The draft guidance is
intended to show how concepts and
tools (e.g., design space) outlined in ICH
Q8 could be put into practice by the
applicant for all dosage forms.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
written or electronic comments on the
draft guidance by April 9, 2008.
ADDRESSES: Submit written comments
on the draft guidance to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
Submit electronic comments to either
http://www.fda.gov/dockets/ecomments
or http://www.regulations.gov. Submit
written requests for single copies of the
draft guidance to the Division of Drug

PO 00000

Frm 00029

Fmt 4703

Sfmt 4703

Number of
responses per
respondent

Average
burden per response
(in hours)

536
1
........................

45/60
6/60
........................

Total burden
(in hours)
5,628
50
5,678

Information (HFD–240), Center for Drug
Evaluation and Research, Food and
Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, or the Office
of Communication, Training, and
Manufacturers Assistance (HFM–40),
Center for Biologics Evaluation and
Research (CBER), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852–1448. The draft
guidance may also be obtained by mail
by calling CBER at 1–800–835–4709 or
301–827–1800. Send two self-addressed
adhesive labels to assist the office in
processing your requests. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance
and other guidances mentioned in this
document.
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Moheb Nasr,
Center for Drug Evaluation and Research
(HFD–800), Food and Drug
Administration, 10903 New Hampshire
Ave., bldg. 21, rm. 2630, Silver Spring,
MD 20993–0002, 301–796–1900; or
Christopher Joneckis, Center for
Biologics Evaluation and Research
(HFM–20), Food and Drug
Administration, 1401 Rockville Pike,

E:\FR\FM\10JAN1.SGM

10JAN1